Literature DB >> 19117781

IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.

Mickey Scheinowitz1, Micha S Feinberg, Zvi Laron.   

Abstract

OBJECTIVE: Untreated patients with congenital growth hormone deficiency (GHD) and IGF-I deficiency are characterized not only by dwarfism but also by acromicria and organomicria, such as the heart. We assessed cardiac dimensions and function in very young patients with Laron syndrome (LS) undergoing IGF-I replacement therapy.
DESIGN: Two to seven echocardiographic measurements were performed during IGF-I replacement therapy on male (n=4) and female (n=4) LS -patients, mean+/-SD age of 7.1+/-3.6 years (range 1.6-11.6 years), weight 16.1+/-9.7 kg, and height 89.9+/-18.5 cm. As aged- and gender-matched controls served 44 healthy children, age: 8.7+/-5.5 years, weight: 36.1+/-22.4 kg, and height: 129.7+/-33.1cm. Data of LS patients were normalized to body surface area and compared to the control group as well as nomograms of normal echocardiographic parameters for this age group.
RESULTS: Left ventricular diastolic and systolic dimensions (LVDD/ LVSD, mm) and LV mass (gr) were significantly smaller in boys and girls with IGF-I treated LS compared with controls while the shortening fraction (%) and intraventricular septum thickness (mm) were similar. When compared with standard values for this age group, all treated LS patients were within 1 standard deviation of the mean.
CONCLUSION: IGF-I therapy of young patients with Laron syndrome maintain LV dimensions and function within the normal range of aged-matched controls.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19117781     DOI: 10.1016/j.ghir.2008.11.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  3 in total

Review 1.  The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances.

Authors:  Zoltan Ungvari; Anna Csiszar
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-26       Impact factor: 6.053

2.  Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides.

Authors:  Mikkel Andreassen; Jens Faber; Andreas Kjær; Claus Leth Petersen; Lars Østergaard Kristensen
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

3.  Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report.

Authors:  Oana R Cotta; Libero Santarpia; Lorenzo Curtò; Gianluca Aimaretti; Ginevra Corneli; Francesco Trimarchi; Salvatore Cannavò
Journal:  J Med Case Rep       Date:  2011-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.